Tue, Feb 06, 2024
Zydus Life said on Monday that it would consider a proposal for buyback of fully paid-up equity shares of the company. The Zydus stock also hit a 52-week high on February 1 and 5, and January 30 and 31.
More >
Mon, Dec 18, 2023
Zydus Lifesciences blasts through the roof, hitting a 52-week high after the US FDA greenlights a Phase II trial for its Parkinson's disease drug ZYIL1! This potential blockbuster medication targets a $2 billion market, setting Zydus on fire.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
